Hikma continues doubling down on its strategic turn towards more complex products and injectables while also forecasting better days for its generics division, based on its recent presentation at this year’s J.P. Morgan Healthcare Conference.
As of now, the company’s injectables division generates “well over” $1bn in revenue, and makes up almost half of Hikma’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?